Jasper Therapeutics reported a net loss for Q3 2025, with ongoing investigations into efficacy results and continued patient enrollment. The company successfully completed a stock offering, extending its cash runway.
Successfully completed a $30 million underwritten offering of common stock and warrants, extending cash runway through the first half of 2026.
positiveInvestigation into anomalous efficacy results suggests no issues with drug substance or drug product manufacturing or distribution.
neutralCash and cash equivalents totaled $50.9 million as of September 30, 2025.
neutralReported a net loss of $18.7 million for the three months ended September 30, 2025.
negativeNet loss per share was $1.13 for the three months ended September 30, 2025, compared to $1.24 in the prior year period.
negativeThe Phase 2b CSU study is now expected to commence mid-2026, a delay from previous expectations.
attentionThe investigation into anomalous efficacy results is ongoing and final conclusions are expected in Q4 2025.
attentionMargin metrics will be available once backend extracts data from insights_json
Focused on advancing programs in chronic urticaria and continuing to believe briquilimab has potential.
Investigation into anomalous efficacy results is nearing completion and encouraged by determination that results are not related to drug substance or product issues.
Plan to complete investigation and report final conclusions in Q4 2025.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.